Amygdala Neurosciences, Inc.
http://www.amygns.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Amygdala Neurosciences, Inc.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
Moderna Makes Major mRNA Commitment To UK
The US biotech major has unveiled plans to open a new research and manufacturing center in the UK, which signals the start of detailed talks with the government about establishing a long-term partnership.
Sanofi’s Uses Latecomer COVID Data To Highlight Bigger mRNA Strategy
The French drug maker isn’t moving its mRNA COVID-19 vaccine into Phase III, instead focusing on a GSK-partnered protein SARS-CoV-2 vaccine and applying mRNA technology elsewhere.
The Factory Floor: Biocon Celebrates Malaysian Insulin Plant Clearance
Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice